These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6971630)

  • 21. Evidence that the stimulus properties of apomorphine are mediated by both D1 and D2 receptor activation.
    Schechter MD; Greer NL
    Life Sci; 1987 Jun; 40(25):2461-71. PubMed ID: 2953944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The discriminative stimulus properties of the D-1 agonist SK&F 38393 and the D-2 agonist (-)-NPA are mediated by separate mechanisms.
    Arnt J
    Life Sci; 1988; 42(5):565-74. PubMed ID: 2963185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.
    Jackson DM; Hashizume M
    Psychopharmacology (Berl); 1986; 90(1):147-9. PubMed ID: 3094056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of selective dopamine receptor agonists in rats trained to discriminate apomorphine from saline.
    Woolverton WL; Kamien JB; Goldberg LI
    Pharmacol Biochem Behav; 1985 Apr; 22(4):577-81. PubMed ID: 3873077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D-1 but not D-2 receptor stimulation of the dorsal striatum potentiates apomorphine-induced jaw movements in rats.
    Koshikawa N; Tomiyama K; Omiya K; de Beltrán KK; Kobayashi M
    Eur J Pharmacol; 1990 Mar; 178(2):189-94. PubMed ID: 1970305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The enantiomers of SK&F 83566, a new selective D-1 dopamine antagonist, stereospecifically block stereotyped behaviour induced by apomorphine and by the selective D-2 agonist RU 24213.
    Molloy AG; Waddington JL
    Eur J Pharmacol; 1985 Oct; 116(1-2):183-6. PubMed ID: 4054213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization.
    Munemura M; Cote TE; Tsuruta K; Eskay RL; Kebabian JW
    Endocrinology; 1980 Dec; 107(6):1676-83. PubMed ID: 6107242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of dopamine agonists in mature and immature rats.
    McDevitt JT; Setler PE
    Eur J Pharmacol; 1981 Jun; 72(1):69-75. PubMed ID: 6973482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dopaminergic agonists and antagonists on the partially contracted, isolated and perfused renal artery of the rat.
    Rodriguez-Mendez SA; Feria M; Boada J
    Pharmacology; 1986; 32(6):321-5. PubMed ID: 3487804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological evidence for the subclassification of central dopamine receptors in the rat.
    Gower AJ; Marriott AS
    Br J Pharmacol; 1982 Sep; 77(1):185-93. PubMed ID: 6889902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement.
    Zarrindast MR; Shahed-Dirin K
    Psychopharmacology (Berl); 1990; 100(2):275-80. PubMed ID: 2305016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects on central dopamine function of chronic L-dopa (methyl ester hydrochloride) treatment of mice.
    Tabar J; Hashizume M; Cook CJ; Beart PM; Jackson DM
    Pharmacol Biochem Behav; 1989 May; 33(1):139-46. PubMed ID: 2789405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways.
    Klemm WR; Block H
    Pharmacol Biochem Behav; 1988 Feb; 29(2):223-9. PubMed ID: 3283778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
    Pettersson I; Liljefors T; Bøgesø K
    J Med Chem; 1990 Aug; 33(8):2197-204. PubMed ID: 1973733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of dopaminomimetics on the secretion of VIP-like immunoreactivity in conscious dogs.
    Goiny M; Uvnäs-Moberg K
    Peptides; 1986; 7 Suppl 1():221-4. PubMed ID: 2875445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of dopamine, apomorphine and piribedil on the mesenterial blood flow of the cat.
    György L; Dóda M
    Arch Int Pharmacodyn Ther; 1985 May; 275(1):22-32. PubMed ID: 4026462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relaxant effect of dopamine on isolated rabbit pulmonary artery.
    Hoshino Y; Obara H; Iwai S
    Life Sci; 1986 Dec; 39(26):2525-31. PubMed ID: 3491945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dopamine receptor agonists and antagonists at peripheral neuronal and vascular dopamine receptors in the anaesthetised dog.
    Hilditch A; Drew GM
    J Cardiovasc Pharmacol; 1984; 6(3):460-9. PubMed ID: 6202973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D-1 receptor activity.
    Pettersson I; Gundertofte K; Palm J; Liljefors T
    J Med Chem; 1992 Feb; 35(3):502-7. PubMed ID: 1531365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on renal dopamine receptors with a new agonist.
    Pendleton RG; Samler L; Kaiser C; Ridley PT
    Eur J Pharmacol; 1978 Sep; 51(1):19-28. PubMed ID: 29762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.